| __timestamp | Regeneron Pharmaceuticals, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 504755000 | 49315000 |
| Thursday, January 1, 2015 | 838526000 | 75043000 |
| Friday, January 1, 2016 | 1177697000 | 83749000 |
| Sunday, January 1, 2017 | 1320433000 | 122682000 |
| Monday, January 1, 2018 | 1556200000 | 207761000 |
| Tuesday, January 1, 2019 | 1834800000 | 284812000 |
| Wednesday, January 1, 2020 | 1346000000 | 317875000 |
| Friday, January 1, 2021 | 1824900000 | 282660000 |
| Saturday, January 1, 2022 | 2115900000 | 451421000 |
| Sunday, January 1, 2023 | 2631300000 | 481871000 |
| Monday, January 1, 2024 | 2954400000 |
Data in motion
In the competitive landscape of biotechnology, understanding the financial strategies of industry leaders is crucial. Over the past decade, Regeneron Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. have demonstrated contrasting approaches to managing Selling, General, and Administrative (SG&A) expenses.
Regeneron has consistently outpaced Sarepta, with its SG&A expenses growing from approximately $500 million in 2014 to over $2.6 billion in 2023, marking a staggering 426% increase. This reflects Regeneron's aggressive investment in administrative and sales capabilities to support its expanding portfolio.
Conversely, Sarepta's SG&A expenses rose from nearly $50 million to $482 million over the same period, a 864% increase, albeit from a smaller base. This indicates a strategic scaling of operations as Sarepta continues to innovate in the field of genetic medicine.
These trends highlight the diverse financial strategies employed by biotech firms to sustain growth and innovation.
Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Sarepta Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited Trends and Insights
Alnylam Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Sarepta Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Sarepta Therapeutics, Inc. and Jazz Pharmaceuticals plc
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and Verona Pharma plc
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs MannKind Corporation Trends and Insights
Sarepta Therapeutics, Inc. or Mesoblast Limited: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Novavax, Inc.
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and Galapagos NV